{"nctId":"NCT00378599","briefTitle":"Effects of Pegylated Interferon Alfa-2b and Ribavirin After Orthotopic Liver Transplantation in Subjects With Chronic Hepatitis C Recurrence (P04590AM3)(COMPLETED)","startDateStruct":{"date":"2006-05"},"conditions":["Liver Transplantation","Hepatitis C, Chronic","Liver Cirrhosis"],"count":125,"armGroups":[{"label":"PEG-Intron plus Rebetol (RBV)","type":"EXPERIMENTAL","interventionNames":["Drug: Combination of (a) pegylated interferon alfa-2b and (b) rebetol"]}],"interventions":[{"name":"Combination of (a) pegylated interferon alfa-2b and (b) rebetol","otherNames":["(a) SCH 54031, PEG-Intron","(b) SCH 18908, Rebetol"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects must confirm that all prior medication washout times have been observed.\n* Subject must be 18 - 70 years of age of either gender and of any race.\n* Subject must be transplanted for end-stage hepatitis C or fulminant hepatitis C.\n* Subject must have documented:\n\n  * persistent HCV viremia after OLT as defined by plasma positive for HCV RNA by quantitative reverse transcription-polymerase chain reaction (RT-PCR),\n  * A liver transplant performed at least 3 months prior to screening but not more than 3 years prior to screening.\n* Subject must be on stable doses of immunosuppression for at least 1 month.\n* Compensated liver disease with minimum hematologic, biochemical, and serologic criteria at the (Day 1) baseline visit.\n\n  * Alpha-fetoprotein value (AFP) less than or equal to 250ng/mL. If AFP greater than 100 ng/mL, patient will need evidence of normal liver (magnetic resonance imaging) MRI and normal chest computerized tomography (CT) scan within the last 3 months or during the screening period.\n* For subjects with a history of diabetes or hypertension, clearance from an ophthalmologist has to be obtained prior to treatment start (Day 1/Visit 2).\n* Subjects with a history of mild depression may be considered for entry into this study.\n* Female subjects cannot be pregnant or breastfeeding and must be either postmenopausal, surgically sterile or using 2 methods of birth control.\n* Sexually active male subjects are practicing an acceptable, method of contraception.\n* Contraceptive measures will be reviewed with female subjects at each visit. Dual methods of contraception must be used for 1 month prior to the start of treatment and 6 months after treatment discontinuation.\n* Pregnancy tests obtained at Screen Visit and Day 1 Visit prior to the initiation of treatment must be negative.\n\nExclusion Criteria:\n\n* Pregnant women, women who plan to become pregnant, male subjects whose partner wants to become pregnant, and breastfeeding women (during study and up to 6 months after study completion).\n* Subject has used any investigational product within 30 days prior to Screening or is participating in any other clinical study.\n* Prior treatment for chronic hepatitis C post-liver transplant, including but not limited to antiviral or immunomodulatory product, any interferon product, or RBV, either as monotherapy or in combination.\n* Subjects with other organ transplants.\n* Any subject who received a positive hepatitis C core antibody (HBcAb) or HCV positive donor liver graft.\n* Retransplantation of the liver for rejection or graft failure.\n* Evidence of decompensated liver disease.\n* Known coagulopathies including hemophilia.\n* Known hemoglobinopathies.\n* Known glucose-6-phosphate dehydrogenase (G6PD) deficiency.\n* Hypersensitivity to alpha interferon and/or RBV.\n* Co-infection with hepatitis B virus (HBV) and/or human immunodeficiency virus (HIV).\n* Evidence of active or suspected malignancy or a history of malignancy within the last 5 years (with the exception of pre-transplant hepatocellular carcinoma histologically within the Milan criteria, and adequately treated basal or squamous cell carcinoma of the skin).\n* Any known pre-existing medical condition that could interfere with the subject's participation in and completion of the study.\n* Subject is or was a substance abuser. Subjects treated with buprenorphine (Subutex) who have been stable for 6 months may be included.\n* Patients weighing over 135 kg;\n\nIs participating in any other clinical study(ies);\n\nIs allergic to or has sensitivity to the study drug or its excipients.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"A Sustained Virologic Response (SVR), Defined as a Plasma HCV RNA Level Below the Lower Level of Quantitation (LLQ) at 24 Weeks Post-treatment","description":"Number of participants with SVR at 24-week follow up after treatment with PEG-Intron and Ribavirin in post-orthotopic liver transplant recipients with recurrent HCV.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":32,"n":125},"commonTop":["ANAEMIA","FATIGUE","HEADACHE","NAUSEA","DIARRHOEA"]}}}